193 related articles for article (PubMed ID: 35644565)
1. Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.
Li M; Xi J; Zhang H; Jin X; Zhang J; Feng M; Zhan C; Wang Q
Ann Thorac Cardiovasc Surg; 2022 Oct; 28(5):320-328. PubMed ID: 35644565
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
[TBL] [Abstract][Full Text] [Related]
3. Impact of a Ground-glass Opacity Component on c-Stage IA Lung Adenocarcinoma.
Li M; Xi J; Sui Q; Kuroda H; Hamanaka K; Bongiolatti S; Hong G; Zhan C; Feng M; Wang Q; Tan L
Semin Thorac Cardiovasc Surg; 2023 Winter; 35(4):783-795. PubMed ID: 35907612
[TBL] [Abstract][Full Text] [Related]
4. Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma.
Aokage K; Miyoshi T; Wakabayashi M; Ikeno T; Suzuki J; Tane K; Samejima J; Tsuboi M
Lung Cancer; 2021 Oct; 160():8-16. PubMed ID: 34365179
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
Xu Y; Zheng M; Wang N; Wang R
Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
[TBL] [Abstract][Full Text] [Related]
6. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Very Small Ground-Glass Opacity Component in Stage IA Solid Predominant Non-small Cell Lung Cancer.
Hattori A; Matsunaga T; Fukui M; Suzuki K; Takamochi K; Suzuki K
Semin Thorac Cardiovasc Surg; 2024 Summer; 36(2):251-260. PubMed ID: 36180013
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
9. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
[TBL] [Abstract][Full Text] [Related]
10. Prognostic influence of a ground-glass opacity component in hypermetabolic lung adenocarcinoma.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
Eur J Cardiothorac Surg; 2022 Jan; 61(2):249-256. PubMed ID: 34632486
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma.
Yang F; Sun K; Li F; Li X; Shi J; Sun X; Hong Y; Jiang G; Zhu Y; Song X
Ann Thorac Surg; 2024 Jun; 117(6):1111-1119. PubMed ID: 37353101
[TBL] [Abstract][Full Text] [Related]
12. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma.
Hattori A; Hirayama S; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
J Thorac Oncol; 2019 Feb; 14(2):265-275. PubMed ID: 30368010
[TBL] [Abstract][Full Text] [Related]
13. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
Lee KH; Chung JH; Cho S; Lee JS; Kim H
Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
[TBL] [Abstract][Full Text] [Related]
14. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.
Hong SJ; Kim TJ; Choi YW; Park JS; Chung JH; Lee KW
Eur Radiol; 2016 Oct; 26(10):3660-8. PubMed ID: 26787602
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors of Recurrence in Patients With Clinical Stage IA Adenocarcinoma Presented as Ground-Glass Nodule.
Su H; Dai C; Xie H; Ren Y; She Y; Kadeer X; Xie D; Zheng H; Jiang G; Chen C
Clin Lung Cancer; 2018 Sep; 19(5):e609-e617. PubMed ID: 29803575
[TBL] [Abstract][Full Text] [Related]
16. Differences in the prognostic implication of ground-glass opacity on CT according to pathological nodal status in lung cancers treated with lobectomy or pneumonectomy.
Park S; Lee SM; Choe J; Choi S; Kim S; Do KH; Seo JB
Eur Radiol; 2022 Jul; 32(7):4405-4413. PubMed ID: 35141781
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implication of consolidation-to-tumor ratio in early lung adenocarcinoma: a retrospective cross-sectional study.
Jing W; Liu M; Li W; Li D; Wu Y; Lv F
Quant Imaging Med Surg; 2024 May; 14(5):3366-3380. PubMed ID: 38720835
[TBL] [Abstract][Full Text] [Related]
18. Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma.
Miyoshi T; Aokage K; Katsumata S; Tane K; Ishii G; Tsuboi M
Ann Thorac Surg; 2019 Jul; 108(1):249-255. PubMed ID: 30876742
[TBL] [Abstract][Full Text] [Related]
19. Solid component ratio influences prognosis of GGO-featured IA stage invasive lung adenocarcinoma.
Sun F; Huang Y; Yang X; Zhan C; Xi J; Lin Z; Shi Y; Jiang W; Wang Q
Cancer Imaging; 2020 Dec; 20(1):87. PubMed ID: 33308323
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer.
Watanabe Y; Hattori A; Nojiri S; Matsunaga T; Takamochi K; Oh S; Suzuki K
J Thorac Cardiovasc Surg; 2022 Mar; 163(3):791-801.e4. PubMed ID: 33516459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
